Video
Is cisplatin eligibility status a factor in the prevalence of patients with UTUC receiving adjuvant therapy?
Author(s):
“There are a few different approaches in perioperative medical chemotherapy or immunotherapy treatment, and it's unclear as to how we should consider all these different approaches,” says Shawn Dason, MD, FRCSC.
Video Player is loading.
In this video, Shawn Dason, MD, FRCSC, discusses the background and findings of the study, “How often does cisplatin ineligibility prevent patients from receiving adjuvant therapy following radical nephroureterectomy for upper tract urothelial carcinoma?” This study was presented at the 2022 Society of Women in Urology Annual Clinical Mentoring Conference. Dason is a urologic oncologist and an assistant professor of urology at The Ohio State University in Columbus.
Related Videos
Sarah Razavi, MD, discusses the physical toll of ureteroscopy on urologists
Study results affirm effectiveness of evolving prostate cancer therapies
Non–Muscle Invasive-Bladder Cancer Overview
Laura Davis, MD, on link between microplastics and bladder cancer
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
Considerations for patient follow-up after onabotA administration
Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
Administering onabotA: Improving patient comfort and easing anxiety
Expert discusses genitourinary syndrome of menopause guidelines
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Related Content
